Pharmabiz55m
EMA committee recommends marketing approval for Novartis oral Fabhalta to treat adults living with C3 glomerulopathy
EMA committee recommends marketing approval for Novartis oral Fabhalta to treat adults living with C3 glomerulopathy: Basel Monday, March 3, 2025, 10:00 Hrs [IST] Novartis announc ...
capitalbrief1h
Small-cap ASX biotech Avecho strikes Sandoz deal for CBD insomnia treatment
An Australian biotech minnow wants to become the first company globally to register an over-the-counter cannabidiol product ...
manilatimes7h
Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies
Additionally, preliminary results from Stage 3 of the OUtMATCH study provide early data on introducing allergenic foods into ...
tbsnews19h
HC adjourns hearing on plea for probing Novartis share transfer till 6 March
Legal notices were served on January 8 to three officials concerned including the Governor of the Bangladesh Bank (BB) urging to stay hand over share of Taka 230 crore of Novartis Bangladesh to Radian ...
Rhumbline Advisers Cuts Stock Position in Novartis AG (NYSE:NVS)
Rhumbline Advisers lowered its position in Novartis AG (NYSE:NVS – Free Report) by 14.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 34,754 shares of the ...